Energy sensing by the AMP-activated protein kinase (AMPK) is of fundamental importance in cell biology. In the pancreatic β-cell, AMPK is a central regulator of insulin secretion. The capacity of the β-cell to increase insulin output is a critical compensatory mechanism in prediabetes, yet its molecular underpinnings are unclear. Here we delineate a complex consisting of the AMPK-related kinase SIK2, the CDK5 activator CDK5R1 (also known as p35) and the E3 ligase PJA2 essential for β-cell functional compensation. Following glucose stimulation, SIK2 phosphorylates p35 at Ser 91, to trigger its ubiquitylation by PJA2 and promote insulin secretion. Furthermore, SIK2 accumulates in β-cells in models of metabolic syndrome to permit compensatory secretion; in contrast, β-cell knockout of SIK2 leads to accumulation of p35 and impaired secretion. This work demonstrates that the SIK2-p35-PJA2 complex is essential for glucose homeostasis and provides a link between p35-CDK5 and the AMPK family in excitable cells.
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. The need for insulin is further enhanced by the phenomenon of insulin resistance, in which insulin signalling pathways in peripheral tissues become defective. Prediabetes, or glucose intolerance, is characterized by mild hyperglycaemia that is maintained by a compensatory increase in insulin secretion from the β-cell compartment. The critical role of the pancreatic β-cell in preventing type 2 diabetes has been further underscored by genome-wide association studies that revealed significant enrichment for genes central to β-cell function as type 2 diabetes susceptibility loci 2 . Indeed, the transition from glucose intolerance/prediabetes to a diagnosis of diabetes occurs when β-cells fail to compensate for the increasing demand for insulin [3] [4] [5] [6] . Understanding and harnessing this innate capacity represents a promising strategy to prevent and treat diabetes, yet mechanistic insight into the functional compensation process remains limited.
A critical role for the tumour suppressor liver kinase B1 (LKB1) as a central regulator of critical aspects of β-cell biology, including cell size, proliferation and insulin secretion has been demonstrated [7] [8] [9] . Biochemical and genetic evidence indicates that LKB1 phosphorylates and activates AMPK, a key regulator of cellular energy metabolism, as well as a large family of AMPK-related kinases. In this regard, although we showed that loss of AMPK activity directly underlies the β-cell hypertrophy and increase in insulin content in LKB1 β-cell knockout mice, precisely how LKB1 regulates insulin secretion is still unclear.
Salt-inducible kinase 2 (SIK2) is an AMPK family member that was originally identified by its homology to SIK1, which accumulated in the adrenal glands of rats fed a high-salt diet 10 . Since then SIK2 has been implicated in diverse biological scenarios, including melanogenesis, mitotic spindle formation, liver steatosis, neuronal survival, cancer progression and gluconeogenesis [11] [12] [13] [14] [15] [16] [17] [18] [19] . SIK2 is thought to exert its biological effects through regulation of gene expression by phosphorylation and inhibition of Creb-regulated transcriptional coactivator (CRTC) proteins, transcriptional coactivators for cyclic AMP response element binding protein (CREB), which itself is essential for β-cell function and survival [20] [21] [22] . To gain insight into the role of SIK2 in the adult β-cell, we generated an inducible, β-cell-specific knockout model and report here that SIK2 is required for glucose-induced insulin secretion and is essential for adaptive β-cell functional compensation in models of hyperglycaemia/obesity. We delineate a pathway wherein SIK2 phosphorylates the cyclin-dependent kinase 5 regulator 1 (CDK5R1; also known as p35), leading to its ubiquitylation by the E3 ligase PJA2 (also known as praja2), required for activation of calcium entry and insulin secretion.
RESULTS

Ablation of Sik2 in adult β-cells results in glucose intolerance
To gain insight into the role of SIK2 in the β-cell, we generated mice with floxed Sik2 alleles and mated them to mice carrying the Pdx1-CreER transgene to generate Sik2 adult β-cell knockout (SABKO) mice. PCR analysis confirmed the specific ablation of the Sik2 gene in islets and not in any other metabolic tissue (Fig. 1a) . Western blotting for SIK2 in isolated islets, cerebral cortex and hypothalamus confirmed that SIK2 protein loss occurred only in the islets of SABKO mice (Fig. 1b) . Furthermore, SABKO mice exhibited nearly complete loss of Sik2 messenger RNA compared with control Sik2 loxP/loxP littermates (S/S), whereas mRNA levels for the remaining SIKs, SIK1 and SIK3, were unchanged ( Supplementary Fig. 1a ). Although islets from SABKO mice exhibited normal morphology and insulin staining (Fig. 1c) , AMPK-mTOR signalling and CRTC2-CREB activity ( Supplementary Fig. 1b-g ), SABKO mice exhibited elevated blood glucose due to a 30% reduction in plasma insulin after refeeding (Fig. 1d) . These changes were seen in both male and female SABKO animals only after tamoxifen treatment, without a change in body weight or insulin sensitivity ( Supplementary Fig. 2a-g ).
Dynamic analysis of glucose clearance in SABKO mice compared with controls was similarly impaired, which we attributed to a 30-40% reduction in plasma insulin levels ( Fig. 1e and Supplementary  Fig. 2h-2k ). Insulin secretion triggered directly by arginine injection was also attenuated in SABKO mice, indicating that loss of SIK2 in β-cells causes a direct insulin secretion defect in vivo (Fig. 1f) . To provoke an increased functional response from the β-cell, control and SABKO mice were fed a high-fat diet (HFD) to mimic conditions of human metabolic syndrome. Although all animals had indistinguishable body weights and food intake after 17-18 weeks on HFD ( Supplementary Fig. 3a, b) , SABKO animals had significantly elevated blood glucose and lower plasma insulin levels after refeeding ( Supplementary Fig. 3c,d ). Interestingly, SABKO mice on HFD also exhibited a pronounced deficiency in glucose clearance compared with control animals (Fig. 1g) , which again correlated with reduced plasma insulin ( Supplementary Fig. 3e ) and became worse with time on HFD (Supplementary Fig. 3f ). These defects were not due to a reduction in β-cell mass ( Fig. 1h and Supplementary Fig. 3g ), or rates of proliferation or apoptosis ( Supplementary Fig. 3h-k) .
First-phase insulin secretion is impaired in SABKO islets
As insulin content in SABKO islets was also unchanged (Fig. 2a) , we suspected that defective insulin secretion may underlie the impaired glucose clearance phenotype. Static glucose-stimulated insulin secretion (GSIS) assays revealed that isolated islets lacking SIK2 secrete ∼40% less insulin following stimulation with glucose (Fig. 2b) . Furthermore, acute inactivation of SIK2 in control islets with lentiviral short hairpin RNA (shRNA) targeting SIK2 reduced GSIS to levels observed from SABKO islets (Fig. 2b ) without affecting content ( Supplementary Fig. 4a ). A reduction in GSIS was also observed in islets following treatment with the pan-Sik inhibitor HG-9-91-01 ( Fig. 2c and Supplementary Fig. 4b ), indicating that SIK2 and not SIK1 or SIK3 is specifically required in the β-cell for insulin secretion. We confirmed these results in the glucose-responsive insulinoma cell line MIN6, in which SIK2 silencing impaired GSIS ( Supplementary  Fig. 4c ), and overexpression of SIK2 wild type (WT) but not a kinasedead SIK2 mutant increased both basal and GSIS without changing insulin content ( Fig. 2d and Supplementary Fig. 4d,e) . Analysis of secretion dynamics from control and SABKO islets by perifusion showed that SABKO β-cells secreted less insulin in the first phase following stimulation with high glucose as well as following direct membrane depolarization with KCl (Fig. 2e) , which was also observed in static GSIS assays (Fig. 2f) . Glucose-stimulated insulin secretion involves oxidation of nutrients and consequent generation of ATP, cell membrane depolarization, extracellular calcium influx, and ultimately insulin granule release [23] [24] [25] . Both mitochondrial respiration (oxygen consumption) and extracellular acidification rate were unchanged in SIK2-knockdown MIN6 cells, indicating that the defect in insulin secretion does not result from impaired cellular energetics or metabolism ( Supplementary Fig. 4f,g ). Taken together, we conclude that there is a specific requirement for SIK2 during first-phase insulin secretion.
SIK2 phosphorylates CDK5R1 (p35)
These data prompted us to identify a SIK2 target required for first-phase insulin secretion at a step downstream of mitochondrial metabolism. We identified an LXBS/TXSXXXL motif, the consensus phosphorylation site for SIK2 (ref. 20) , surrounding Ser 91 of CDK5R1 (p35) (Fig. 3a) . p35 is an activator of the atypical cell cycle kinase CDK5, which is enriched in the nervous system and also inhibits insulin secretion in the β-cell by blocking calcium ion influx [26] [27] [28] [29] . We confirmed that FLAG-SIK2 WT, but not a kinase-dead FLAG-SIK2 mutant, directly phosphorylates recombinant p35 WT in vitro (Fig. 3b) , which is prevented by mutation of Ser 91 to alanine (Fig. 3c) . When we evaluated the effect of a panel of inhibitors targeting SIKs, AMPKs, CDKs, CAMK and PKA in this setting, only MRT199665 and HG-9-91-01, which share overlapping specificity for all SIKs1-3, blocked p35 phosphorylation (Fig. 3d) . To rule out that a kinase copurifying with SIK2 was responsible for the phosphorylation of p35 at Ser 91, we used recombinant SIK2 protein purified from baculovirusinfected insect cells and again only p35 WT, but not the S91A mutant, was phosphorylated (Fig. 3e) . Furthermore, phosphorylation of p35 was blocked by treatment with the Sik inhibitor HG-9-91-01 (Fig. 3e) . Western blotting with phospho-specific Ser 91 antibody revealed that silencing SIK2 reduced phosphorylation of overexpressed p35-V5 at Ser 91 in MIN6 cells (Fig. 3f) . Detection of phospho-Ser-91 on endogenous p35 proved more challenging; however, we noticed that when SIK2 was silenced, endogenous p35 protein accumulated (Fig. 3g) . When we included the 26S proteasome inhibitor MG132 in the culture medium, we detected phospho-Ser-91 on endogenous p35, which was reduced when SIK2 was silenced (Fig. 3h) . Taken together, these data indicate that SIK2 directly phosphorylates p35 at Ser 91.
PJA2 ubiquitylates p35
We next evaluated the role of the phosphorylation at Ser 91 by SIK2 in the regulation of p35 protein stability. When we overexpressed SIK2, and CellMask blue cytoplasmic/nuclear stain (blue). Scale bars: 100 µm. Right, quantification of β-cell area in S/S (n = 4 mice) and SABKO (n = 4 mice) mice. All error bars represent s.e.m. Statistical significance for all data was determined using two-tailed unpaired Student's t-test ( * P < 0.01, * * P < 0.05). Data in a-c are representative of two independent experiments. The statistics source data for h are provided in Supplementary Table 1 . Uncropped images of blots/gels are shown in Supplementary  Fig. 9 . levels of p35 decreased, an effect that required the kinase activity of SIK2 and Ser 91 of p35 (Fig. 4a) . To determine whether SIK2 triggers degradation of p35 following phosphorylation at Ser 91, we monitored p35 levels in the presence of MG132 (ref. 30) . Following MG132 treatment, p35 levels increased even in the presence of SIK2 WT, indicating that phosphorylation of p35 at Ser 91 by SIK2 leads to p35 turnover by the proteasome (Fig. 4a) . When cells were treated with MG132, we detected polyubiquitylation of p35-V5 WT but not the S91A mutant (Fig. 4b) , demonstrating that phosphorylation of p35 by SIK2 leads to its polyubiquitylation. Consistent with this, p35 protein also accumulated in SABKO islets as well as in WT islets following pharmacological inhibition of SIKs with HG-9-91-01 (f) Insulin secretion from S/S (n = 3 mice) and SABKO (n = 3 mice) islets treated with low (2.8 mM) and high (16.7 mM) glucose, and 45 mM KCl for 1 h. All error bars represent s.d. Statistical significance for all data was determined using two-tailed unpaired Student's t-test ( * P < 0.01, * * P < 0.05). The statistics source data for a-c,f) are provided in Supplementary  Table 1 . Uncropped images of blots/gels are shown in Supplementary  Fig. 9 . (Fig. 4c) . Silencing of AMPKα1, LKB1, SIK1 or SIK3 in MIN6 cells had no effect on p35 accumulation; thus, we conclude that SIK2 has a specific role in regulating p35 stability (as with GSIS, shown above; Supplementary Fig. 5a -c). We next used a proteomic approach to identify proteins that interact with p35, and we identified PJA2 (also known as Praja2 or Neurodap1) 31 as a candidate ubiquitin E3 ligase for p35. Whereas silencing PJA2 led to the accumulation of endogenous p35 (Fig. 4d) , overexpression of FLAG-PJA2 WT but not a catalytically inactive mutant reduced levels of p35-V5 protein, an effect that was blocked by MG132 treatment (Fig. 4e) . Importantly, silencing either SIK2 or PJA2 resulted in a reduction in polyubiquitylation of p35 (Fig. 4f) . Furthermore, silencing PJA2 prevented degradation of p35 that occurred in cells overexpressing SIK2 (Fig. 4g) . Taken together, these data show that SIK2 reduces p35 protein abundance by promoting its ubiquitylation by the E3 ligase PJA2.
The SIK2-p35-PJA2 complex is required for calcium mobilization in the β-cell
We next examined the consequence of modulating SIK2-p35 signalling on β-cell function. Consistent with a previous report 26 , silencing p35 enhanced insulin secretion in MIN6 cells cultured in high glucose without affecting insulin content ( Fig. 5a and Supplementary Fig. 6a ). In contrast, overexpression of p35 WT reduced GSIS, an effect that was more pronounced with the S91A construct ( Fig. 5b and Supplementary Fig. 6b ). Silencing SIK2 in MIN6 cells increased phosphorylation of Ser 783 on the critical p35-CDK5 target voltage-dependent calcium channel (VDCC; Fig. 5c ), which correlates with inhibition of channel activity 26 . A similar increase in pVDCC signal was also observed in SABKO islets ( Supplementary  Fig. 6c ). We observed reduced calcium influx following overexpression of p35 (Fig. 5d ) or silencing SIK2 (Fig. 5e ) in MIN6 cells, consistent with a requirement for SIK2 to turnover p35. Silencing p35 in WT islets similarly led to an increase in calcium influx, and rescued the impaired calcium entry phenotype observed in SABKO islets (Fig. 5f ). Furthermore, PJA2 knockdown similarly resulted in an increase in pVDCC levels and impaired calcium entry in MIN6 cells (Fig. 5g,h) . Co-immunoprecipitation experiments demonstrated that not only SIK2 and p35, but p35 and PJA2 form a complex in MIN6 cells (Fig. 5i) . Taken together, we conclude that the signalling cassette consisting of SIK2-p35-PJA2 regulates calcium entry in the β-cell through phosphorylation of VDCC in response to glucose.
The SIK2-p35-PJA2 complex is required for insulin secretion
As noted above, calcium entry is a critical trigger in the classical GSIS pathway. This prompted us to look at the requirement for the SIK2-p35-PJA2 complex in insulin secretion. Silencing p35 restored normal insulin secretion in SABKO islets (Fig. 6a) as did pharmacological inhibition of CDKs with olomoucine (Fig. 6b) . For its part, silencing PJA2 also reduced GSIS in MIN6 cells and islets by 50%, without reducing insulin content ( Fig. 6c and Supplementary Fig. 7a-c) . Importantly, silencing p35 in PJA2-knockdown cells rescued the insulin secretion defect (Fig. 6d) , as did treatment with olomoucine ( Fig. 6e) , consistent with the notion that PJA2 promotes GSIS by A R T I C L E S turning over p35. Taken together, these data support a direct role for the SIK2-p35-PJA2 cassette in the regulation of insulin secretion in the β-cell.
SIK2 is required for β-cell functional compensation
The requirement of SIK2 for effective glucose homeostasis prompted us to evaluate the status of SIK2 in animal models of obesity and prediabetes. Western blot analysis of SIK2 protein in islets from ob/ob mice 32 increases 2.5-fold compared with islets from B6 controls, without a change in SIK2 mRNA (Supplementary Fig. 8a ). Elevated SIK2 with a concomitant reduction in p35 was also seen in islets from mice on a HFD (Fig. 7b) . Importantly, silencing SIK2 in ob/ob islets reduced the insulin hypersecretion phenotype of islets from ob/ob mice (Fig. 7c,d ). As insulin content was also unaffected by Statistical significance for all data was determined using two-tailed unpaired Student's t-test ( * * P < 0.05). All western blot data are representative of three independent experiments with consistent results. The statistics source data for c are provided in Supplementary  Table 1 . Uncropped images of blots/gels are shown in Supplementary  Fig. 9 . Statistical significance for all data was determined using two-tailed unpaired Student's t-test ( * P < 0.01, * * P < 0.05). The statistics source data for a-c are provided in Supplementary Table 1. Uncropped images of blots/gels are shown in Supplementary Fig. 9 . (Supplementary Fig. 8b ), we conclude that functional adaptation of islets to hyperglycaemia requires higher levels of SIK2. The common feature of hyperglycaemia in the ob/ob and HFD models prompted us to evaluate whether SIK2 is regulated by glucose. SIK2 protein levels were low after overnight culture in low glucose and increased directly as a function of ambient glucose concentration, an effect that was blocked by treatment with 2-deoxyglucose, an inhibitor of glycolysis (Fig. 7e) . Whereas treatment of MIN6 cells with the mTOR inhibitor rapamycin had no effect in this setting, proteasome inhibition in MIN6 and islets increased SIK2 levels in low glucose (Fig. 7f) . As in vitro kinase activity present in SIK2 immunoprecipitates correlated with the amount of total SIK2 protein, we conclude that the intrinsic activity of SIK2 is not regulated by glucose (Fig. 7g) . SIK2 mRNA levels were the same in WT and ob/ob mice, suggesting that transcription or mRNA stability played no role in this setting ( Supplementary  Fig. 8c ). We next analysed SIK2 protein levels in islets isolated from diabetic mice that exhibit impaired GSIS. Interestingly, the SIK2 protein is reduced in islets from db/db mice on the BKSDock7 m background, indicating an uncoupling between glucose levels and SIK2 accumulation (Fig. 7h) . These data are consistent with the notion that stabilization of SIK2 is required to maintain insulin secretion in the face of dietary or genetic predisposition to obesity. Bottom, western blot analysis of SIK2 protein levels in islets from BKS and db/db mice. Statistical significance for all data was determined using two-tailed unpaired Student's t-test ( * P < 0.01, * * P < 0.05). All western blot data are representative of two or three independent experiments with consistent results. The statistics source data for d,h are provided in Supplementary  Table 1 . Uncropped images of blots/gels are shown in Supplementary Fig. 9 .
A R T I C L E S
SIK2 silencing in this context
DISCUSSION
Here we have delineated a pathway essential for first-phase insulin secretion and for functional compensation in the β-cell wherein calcium entry is coordinated in response to hyperglycaemia through SIK2 and PJA2. Following glucose stimulation, this kinase-E3 ligase module targets p35, an essential activator of CDK5, to relieve inhibitory phosphorylation of VDCC and activate calcium influx 26 . The linearity of this pathway is supported by genetic evidence, whereby silencing p35 can rescue defects in calcium entry and insulin secretion resulting from silencing SIK2 or PJA2. Interestingly, PJA2 is activated by the second messenger cAMP (ref. 33) , which accumulates in the β-cell in response to incretin hormone stimulation and crosstalk with glucose-calcium signalling 34 . Our data place PJA2 in the insulin secretion pathway and raise the possibility that PJA2 is a central regulator of β-cell function.
The AMPK family consists of 14 kinases, including three SIKs, raising the possibility of redundancy within the family 35 . However, regulation of both p35 levels and insulin secretion seems to be unique to SIK2, as knockdown of SIK1 and SIK3 had no effect in this regard ( Supplementary Fig. 8d,e) , and treatment with pan-Sik inhibitor had no affect on insulin secretion in islets lacking SIK2. In all cell types, AMPK is activated under low-energy conditions to mobilize energy stores, and in the β-cell acts to restrain protein synthesis and insulin production under the control of the upstream AMPK kinase, LKB1 7, 8, 36 . In contrast to LKB1, ablation of SIK2 in the β-cell had no effect on mTOR signalling, and in return, mTOR signalling seems not to contribute to SIK2 accumulation in high glucose. Interestingly, recent work has also shown that the AMPK family member Sad-A (also known as Brsk2) mediates mTOR signalling to promote β-cell size and function 37 . For its part, AMPK activity was reduced yet its protein levels unchanged in high glucose, consistent with our previous work 7 . Our observation that the SIK2 protein accumulates in excess glucose without effect on its intrinsic activity indicates that there is diversity within the AMPK family both in the response to nutrient status and effects on insulin secretion. As SIK2 is ubiquitously expressed, its responsiveness to ambient glucose concentrations has implications for scenarios in which cells depend on glycolytic metabolism as a primary energy source. Taken together, Left, AMPK-mTOR signalling: in response to glucose, AMPK catalytic activity is inhibited owing to an increase in the ATP/AMP ratio. This in turn leads to depression of mTORC1 and insulin biosynthesis. Right, the SIK2-p35-CDK5-PJA2 pathway: unlike AMPK, SIK2 protein, and in turn its net activity, increases with high glucose. SIK2 phosphorylates p35 at Ser 91, which triggers its ubiquitylation by the E3 ligase PJA2, resulting in activation of calcium signalling and insulin secretion. Uncropped images of blots/gels are shown in Supplementary Fig. 9 .
our data indicate that the net effect of glucose stimulation on the AMPK family is to promote insulin production and secretion through inhibition of AMPK and accumulation of SIK2 (Fig. 8) .
From an organism perspective, our data demonstrating that SIK2 is required for insulin secretion are consistent with the recent observation that SIK2 and SIK3 in Drosophila regulate anabolic effects through antagonism of the Hippo pathway 38 . Although SIKs have also been reported to regulate energy storage in the brain and fat in the fly through repression of FOXO1 and CREB gene expression programs [39] [40] [41] , we observe unaltered CRTC2 phosphorylation and CREB target gene activation in SABKO islets. Thus, SIK2 functions to regulate secretory events, but not CREB-dependent gene expression in the β-cell.
Our work provides a mechanistic framework for understanding β-cell functional adaptation. Dynamic analyses of human islet function following nutrient stimulation has revealed that impaired first-phase insulin release is a hallmark of type 2 diabetes, and progressive impairment of first-phase secretion occurs as β-cells fail to compensate for the increasing demand [3] [4] [5] [42] [43] [44] [45] [46] [47] . That SIK2 is causally linked to enhanced insulin secretion is highlighted by the reversal of hypersecretion following silencing of SIK2 in islets isolated from obese mice. Furthermore, the accumulation of SIK2 in islets from compensating mice and the reduction of SIK2 in islets from diabetic mice that show secretory impairment highlights the importance of this pathway.
Neurons and β-cells share several common features, including ontology, electrical excitability, and use of cAMP and calcium signalling pathways 48 . Unlike SIK2, p35 appears exclusively in brain and islets, and accumulates in both tissues in the absence of SIK2, indicating conservation of the p35-SIK2 cassette in these settings ( Supplementary Fig. 8f,g ) In the brain, the p35-CDK5 complex is required for central nervous system development and the pain response, and aberrant CDK5 activity is associated with ischaemic stress and Alzheimer's disease 49 . Emerging evidence indicates that CDK5 is also a key metabolic regulator 50 and potential target for antidiabetes drugs 51 . Our work provides the first link between the energysensing LKB1-AMPK family and p35-CDK5, two key regulatory networks in excitable cell biology, and suggests that activating SIK2 and PJA2 in the β-cell may be beneficial for treatment of symptoms associated with insulin deficiency.
DOI: 10.1038/ncb2919 M E T H O D S METHODS
Mice. Sik2
loxP/loxP mice (C57BL6/129sv background) carrying loxP sites flanking exons 5-7 (exon 5 encodes the activation loop) were backcrossed four times onto the FVB/n background, and then mated to Pdx-CreERt2 mice (FVB/n background) to generate Sik2 loxP/loxP , Pdx-CreERt2 + mice and appropriate controls. To induce Sik2 gene ablation, 5 mg of tamoxifen (Sigma) per 40 g body weight was injected intraperitoneally every second day for a total of 3 injections, as described previously 7 . Unless otherwise stated, analyses were performed starting 7-10 days after the last injection. Both male and female mice were used for the analyses. To confirm the deletion of the Sik2 gene, PCR analysis was performed using genomic DNA purified from various tissues of S/S and SABKO mice. To detect the deletion of the Sik2 gene and the floxed-Sik2 allele, the following primer sets were used: Sik2-deleted allele (Sik2 I4F: 5 -GCTGTTACCAGGTTCTCAATTGTCTC-3 and Sik2 I7R: 5 -GGCAGACAGGGCAAAGGAAGG-3 ) and floxed-Sik2 allele (Sik2 E7F: 5 -GATCAGCAGAAGACTGTTGAGG-3 and Sik2 I7R: 5 -GGCAGA CAGGGCAAAGGAAGG-3 ). The following primer sets were included in the reaction as an internal control (Gabra70: 5 -AACACACACTGGCAGGACT GGCTAG-3 and Gabra12: 5 -CAATGGTAGGCTCACTCTGGGAGATG-3 ). To generate Sik2 whole-animal KO mice, animals homozygous for the Sik2 loxP allele were crossed with mice carrying the Hprt-Cre transgene. Tissues were isolated from 6 to 10-wk-old Sik2 loxP/loxP ; Hprt-Cre + mice and snap frozen in liquid nitrogen before use. All procedures involving mice were approved by the Animal Care Committee of the University of Ottawa. For high-fat diet studies, mice were fed normal laboratory diet or high-fat diet (45 kcal% fat; Open Source Diets) for 16-20 weeks as indicated. B6.v-Lepob/J, C57BL/6J, BKS.Cg-Dock7m +/+ Leprdb/J and BKS.Cg-Dock7 mice were purchased from The Jackson Laboratory. In all animal experiments, no statistical method was used to predetermine sample size and the experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
Cell culture and reagents. HEK293T and MIN6 cells (p. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] were obtained from ATCC and provided by S. Seino (Kobe University, Japan), respectively, and cultured in DMEM + 10% FCS + antibiotics in a humidified atmosphere with 5% CO 2 . MIN6 medium was supplemented with 100 µM β-mercaptoethanol. For plasmid transfection, HEK293T cells were transfected using PEI (Sigma) or Lipofectamine 2000 (Invitrogen). Mouse islets were cultured in RPMI-1640 supplemented with 10% FCS and antibiotics. Rapamycin was from LC Laboratories. MG132 and thapsigargin were from Sigma-Aldrich. Olomoucine and KN-93 were from Calbiochem. H89 was from Cell Signaling Technology. Pan-Sik inhibitor HG-9-91-01 and MRT199665 were provided by P. Cohen (University of Dundee, UK). Recombinant SIK2 (SRP5082) was from Sigma-Aldrich. Antibodies: polyclonal SIK2 antiserum 'E1'-targeting peptide TQYLQHRLQKPNLLPKA was generated with the Covance custom antibody service and used following affinity purification. A second affinity-purified SIK2 antibody was provided by O. Göransson (Lund University, Sweden). Anti-serum against phospho-p35 (Ser 91) and phosphorylated and unphosphorylated peptides of p35 (KKSL(p)SCANLSC and KKSLSCANLSC) were provided by S. Hisanaga (Tokyo Metropolitan University, Japan). Anti-phospho-VDCC (Ser783) was a gift from K. Tomizawa (Kumamoto University, Japan). Anti-β-actin (AC-15, 1:5,000), normal rabbit IgG, anti-FLAG (M2, 1:2,000) and anti-VDCC (C1603, 1:500) antibodies were from Sigma. Anti-V5 (46-0705, 1:5,000) was from Invitrogen. Anti-p35 (C64B10, 1:1,000), ubiquitin (P4D1, 1:2,000), phospho-S6K (Thr 389) (number 9205, 1:1,000), phospho-rpS6 (Ser 235/236; D57.2.2E, 1:1,000), rpS6 (54D2, 1:2,000), phospho-eEF2 (Thr 56) (number 2331, 1:1,000), eEF (number 2332, 1:2,000), phospho-AMPK (Thr 172) (number 2531, 1:1,000), AMPKα (F6, 1:2,000), phospho-ACC (number 3661, 1:1,000), ACC (number 3662, 1:1,000), cleaved caspase-3 (number 9661, 1:1,000) were from Cell Signaling Technology. Anti-LKB1 (Ley 37D/G6, 1:1,000) and S6K (C-18, 1:1,000), p35 (C-19) and Hsp90α/β (H-114, 1:2,000) were from Santa Cruz. Anti-PJA2 (A302-991A, 1:2,000) was from Bethyl Laboratories. CRTC2 and phospho-CRTC2 (Ser 171 and Ser 275) were described previously 52 .
Glucose tolerance, insulin tests and immunohistochemistry. Animals were fasted for 16 h before intraperitoneal injection with 2 mg g −1 body weight (chow diet) or 1.75 mg g −1 body weight of glucose (high fat diet), and blood glucose and insulin levels were measured at the indicated times as described previously 7 . Plasma insulin levels were measured by ELISA using an ultra-sensitive mouse insulin kit (Crystal Chem). For measurement of fasted and refed blood glucose and insulin levels, mice were fasted for 16 h, then refed for 2 h. For arginine injection, mice were fasted for 16 h, and then injected intraperitoneally with1 mg g −1 body weight of L-arginine (Sigma). For insulin tolerance tests, mice were fasted for 4 h, and then injected intraperitoneally with 0.6 U kg −1 body weight of insulin (NovoRapid, Novo Nordisk). Immunohistochemistry was performed as described previously 7 . To measure β-cell mass, pancreatic sections were stained with anti-insulin (A0564 Dako, 1:200) and CellMask Blue cytoplasmic/nuclear stain (H34558 Invitrogen, 2 µm ml −1 ). CellMask Blue cytoplasmic/nuclear stain was used to stain whole pancreatic tissue. β-cell and whole pancreatic tissue areas were measured using Fiji software.
RNA interference and cDNA plasmids. shRNAs targeting SIK2 and CDK5R1
were packaged in HEK293T cells cultured in 15-cm dishes using pLKO.1, pCMV8.3 and pMD2.G vectors. Seed sequences of shRNAs (in pLKO.1) were as follows: mSIK2 number 1: 5 -CCTGGACTCTTTGATTGTGAA-3 ; mSIK2 number 2: 5 -CAAGACGGAGGTGGCTATAAA-3 ; mCDK5R1 number 1: 5 -CCC ACGTTAGTGCTGGTTAAT-3 ; mCDK5R1 number 2: 5 -ACGATGGATCCAGG GTAGATG-3 ; mLKB1: 5 -CGCCAAGCTCATCGGCAAGTA-3 ; mAMPKα1: 5 -CCCATCTTATAGTTCAACCAT-3 ; mSIK1: 5 -CTGGGACTGAACAAGATCAA A-3 ; mSIK3: 5 -CGGAATATCGTTCATCGTGAT-3 ; mPJA2 number 1: 5 -CG GAGAGTATTACCAACTCTT-3 ; mPJA2 number 2 (hPJA2 number 1): 5 -GCCA GTAAGGAAAGCATTGAT-3 ; hPJA2 number 2: 5 -GAATGGCTGTGGAGATTA TTA-3 ; control shRNA2: 5 -GCGCGATAGCGCTAATAATTT-3 . Control shRNA1 was from Sigma. Virus was concentrated 100X by ultracentrifugation at 28, 000g for 2 h with a lower 20% sucrose layer as described previously 22 . Virus was resuspended at 4 • C overnight and stored in aliquots at −80 • C for use. For overexpression, cDNA encoding mouse SIK2 WT, K49M, and S587A as well as mouse p35 WT and S91A was inserted into pDONR211 vector (Invitrogen), and then Gateway recombined into pLenti6-V5 vector (Invitrogen) according to the manufacturer's instructions. Cells were infected with lentivirus for 30-96 h.
Glucose-stimulated insulin secretion. GSIS assays were performed as described previously 7 .
Co-immunoprecipitation, SDS-PAGE and western blotting. HEK293T or MIN6 cells were lysed in ice-cold (all steps were performed at 4 • C) coimmunoprecipitation buffer (20 mM HEPES-KOH, at pH 7.5/150 mM NaCl/2 mM EDTA/1% Triton X-100) containing halt protease inhibitor cocktail (Thermo Scientific) and the whole-cell extracts were precleared with Protein A/G agarose (Santa Cruz) for 2 h. Precleared lysates were incubated with 3 µg of anti-SIK2 (E1) antibody or control rabbit IgG overnight, before incubation with 30 µl of Protein A/G agarose (50% slurry) for 2 h. After washing 3 times with co-immunoprecipitation buffer, immunoprecipitates were resolved by SDS-PAGE, followed by immunoblot analysis as described previously 7 . For glucose treatments, islets were starved with 2.8 mM glucose for 2 h and then treated with the indicated concentrations of glucose for 1 h before extract preparation. Quantification of western blotting results was performed on ImageJ software. Data presented are representative of at least two independent experiments.
Measurements of intracellular free Ca 2+ concentration ([Ca 2+ ] i ).
Measurements were performed as described previously 7 .
In vitro kinase assay. Assays were performed as described in ref. 52. Purified GST-p35 WT and S91A proteins were incubated with FLAG-SIK2 (purified from HEK293T cells) immobilized on protein A/G agarose in kinase assay buffer at 30 • C for 20 min before SDS-PAGE and autoradiography. Proteins were visualized by SimplyBlue safe stain (Invitrogen).
Quantitative PCR with reverse transcription. Assays were performed on a
Mastercycler EP Realplex 2 (Eppendorf) using a QuantiTect SYBR green PCR kit (Qiagen). Relative gene expression was determined by CT normalized to expression of 36b4. The following primer sets were used: mouse SIK1 (5 -GCCTTGT ACCTCGACTCTGC-3 and 5 -CCCCCAAGTCAGGTGTTCTA-3 ), mouse SIK2 (5 -GCAGCTCACAACCCCATTGTG-3 and 5 -GGACTTCAGGACACCGCATC-3 ), mouse SIK3 (5 -TCCTCACCTGGTACCTGACC-3 and 5 -CAGGGTGTTGGA GTCCTTGT-3 ), mouse Nr4a2 (5 -CGACCTCTCCGGCCTTTTA-3 and 5 -CGCC GAAATCGTTGTCAGTA-3 ), mouse Irs2 (5 -AGCTTTGATTGGCTGTCCTGG AG-3 and 5 -TGGCGATATAGTTGAGGCCGTTGT-3 ), mouse 36b4 (5 -CCACG AAAATCTCCAGAGGCAC-3 and 5 -ATGATCAGCCCGAAGGAGAAGG-3 ). Primer sets of SIK1 and SIK3 were designed using Primer3. RNA from islets isolated from 3 different mice of the same genotype was pooled to have sufficient material to generate cDNA for qRT-PCR.
Mitochondrial stress test. MIN6 cells were infected with lenti-shRNA targeting SIK2 or non-silencing control on Seahorse XF24 cell culture microplate on day 0. On day 3, cells were starved in 400 µl of Seahorse XF assay medium containing 1 mM glucose for 30 min, and oxygen consumption measured following treatment with 20 mM glucose, 0.5 µM FCCP and rotenone (0.5 µM) at the indicated times. Protein was quantified using BCA (Thermo Scientific) for normalization.
Measurement of MIN6 cell proliferation. MIN6 cells were infected with control or SIK2 shRNA. After 72 h of infection, cells were fixed with 3.7% formaldehyde and stained with anti-Ki67 antibody (41-5698-80 eBioscience, 1:1,000) and Hoechst 33342 (H3570 Invitrogen, 10 µg ml −1 ). For EdU staining, MIN6 cells were treated with 10 µM EdU for 4 h before fixation. EdU staining was performed according to the manufacturer's instructions (C10340 Invitrogen). Fluorescent imaging and quantification were carried out as described previously 22 .
Statistical analyses.
All studies were performed on at least three independent occasions. Results are reported as mean ± s.e.m. Statistical significance for all data was determined using two-tailed unpaired Student's t-test; P values < 0.05 were considered significant. Significance in all figures is indicated as follows: * P < 0.01, * * P < 0.05.
Repeatability of experiments.
All experiments were conducted at least twice and consistent results were obtained.
Proteomic analysis. Cells expressing FLAG-CDK5R1 (wild-type or a S91A mutant) or the tag alone were treated with MG132 or left untreated. Biological duplicates (for each construct and treatment) were purified by anti-FLAG purification on magnetic beads, and trypsin digestion directly on the beads, as described previously 53 . The samples were analysed on an AB Sciex mass spectrometer. Data files were analysed using the Mascot search engine (2. 
